The main goal of our study was to introduce new diagnostic tools, potentially suitable for IVD certification—an antibody for the detection of CA IX in IHC and an ELISA kit for the detection of sCA IX in the plasma—and to verify their diagnostic properties on a cohort of 100 patients with primary operable early BC. Here, CA9 is linked to breast cancer.